
-- | |
$19.84 | |
$73.60 | |
$0.42 | |
$19.84 | |
$-1.00 | |
-5.04% | |
450K |
Attovia Therapeutics, Inc. (ATTO) is currently trading at $18.88 as of 2026-08-12 00:00:00, reflecting a -5.04% move ($-1.00) from the previous close.
In the short term, the stock has returned -13.81% over the past four weeks. Over the last 12 months, Attovia Therapeutics, Inc. has recorded a -13.81% price change, indicating a Weak performance relative to the broader market.
Over the past seven days, Attovia Therapeutics, Inc. has traded within a short-term range shaped by market sentiment in the sector. During this period, the stock moved from its previous closing price of $21.00 to the latest recorded price of $18.88, reflecting an intraday change of -5.04%. Daily movements highlight shifts in trading volume (450,495), investor positioning, and reactions to macroeconomic updates.
From a momentum standpoint, ATTO has delivered a -13.81% return over the past month and a -13.81% change in the last 12 months, indicating a Weak trend relative to its broader sector peers.
You can buy and trade ATTO on MEXC in three simple steps:
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
| Industry | -- |
| Employees | -- |
| Sector | -- |
| Company Website |
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.